Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
Open Access
- 8 February 2021
- Vol. 11 (2), e044711
- https://doi.org/10.1136/bmjopen-2020-044711
Abstract
Introduction Bile acid malabsorption (BAM) is a socially debilitating disease characterised by high stool frequency and urgency caused by a spillover of bile acids into the colon. Bile acid sequestrants (BASs) have limited therapeutic effect but represent the only available treatment option. Cases reporting total remission of BAM-related symptoms after treatment with liraglutide, a glucagon-like peptide 1 analogue, prompted us to design a clinical trial investigating the therapeutic effect of this compound in patients with BAM. Methods and analysis Fifty adult individuals with moderate or severe BAM as assessed by the 75selenium-homotaurocholic acid test (SeHCAT) will, after a run-in period of 10 days with no BAM treatment, be randomised to either treatment with the BAS colesevelam or liraglutide (double blinded) for 6 weeks. Daily symptom diaries and questionnaires will be filled in. Blood and faecal samples will be collected and SeHCAT will be performed at baseline, after week 3 and at end of trial. The primary endpoint is change in daily stool frequency. Secondary endpoints include changes from baseline in questionnaires, biochemistry, SeHCAT and faecal bile acid content and microbial composition. Ethics and dissemination The study complies with Danish and European Union legislation and is approved by the Danish Medicines Agency, the Regional Scientific Ethics Committee of the Capital Region of Denmark and the Danish Data Protection Agency. The study is monitored by the Capital Region of Denmark’s good clinical practice unit. All results, positive, negative and inconclusive, will be disseminated at national and/or international scientific meetings and in peer-reviewed scientific journals. Trial registration number EudraCA: 2018-003575-34; Pre-results.Keywords
This publication has 33 references indexed in Scilit:
- Methods for Diagnosis of Bile Acid Malabsorption in Clinical PracticeClinical Gastroenterology and Hepatology, 2013
- Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patientsHealth and Quality of Life Outcomes, 2013
- Managing bile acid diarrhoeaTherapeutic Advances in Gastroenterology, 2010
- A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid BiosynthesisClinical Gastroenterology and Hepatology, 2009
- Recent advances in the understanding of bile acid malabsorptionBritish Medical Bulletin, 2009
- Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2009
- GLP‐1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndromeNeurogastroenterology & Motility, 2008
- Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasisCell Metabolism, 2005
- Irritable bowel syndromeBritish Medical Bulletin, 2004
- Bile Acid Malabsorption in Patients with Chronic Diarrhoea: Clinical Value of SeHCAT TestScandinavian Journal of Gastroenterology, 2003